Microvascular and macrovascular complications, such as kidney disease and atherosclerotic disease, are major causes of morbidity and mortality associated with type 2 diabetes (T2D). Diabetes results in a doubling of cardiovascular risk, 1 but the mechanisms whereby diabetes accelerates the underlying process of atherosclerosis are not fully understood. In addition to cardiovascular complications, diabetes is the leading cause of chronic kidney disease and renal failure, and at least 35% of adults with T2D have diabetic kidney disease (DKD), defined as albuminuria or an impaired estimated glomerular filtration rate. 2 The presence of kidney disease also increases the risk of cardiovascular events in patients with and without diabetes 3, 4 ; however, the interactions between DKD and atherosclerosis are not clear, partly because few animal models that accurately reflect human DKD exist. Although many mouse models of atherosclerosis are available, few are models of T2D-acclerated atherosclerosis, and no model also exhibits DKD. The black and tan, brachyury (BTBR) mouse strain with leptin deficiency [Lep ob (OB)] has emerged as one of the best models of human DKD because in addition to exacerbated albuminuria it features morphologic characteristics of DKD, such as increased mesangial matrix deposition and sclerosis, mesangiolysis, podocyte loss, and macrophage accumulation. 5 However, BTBR mice do not develop significant atherosclerosis 5 because of the low levels of low-density lipoprotein (LDL) compared with high-density lipoprotein (HDL). The traditional strategy to render mouse models susceptible to atherogenesis is to reduce clearance of LDL via timeconsuming and costly breeding to mice deficient in apolipoprotein E or the LDL receptor (Ldlr À/À mice). This results in a more human-like lipoprotein profile and increased LDL levels compared with HDL levels. 6e8 Recently, novel pathways that reduce LDL receptor levels and thus increase LDL cholesterol (LDL-C) and total cholesterol levels have been discovered. One such pathway involves the E3 ubiquitin ligase inducible-degrader of the LDL receptor (IDOL). 9, 10 IDOL targets the LDL receptor for ubiquitin-mediated lysosomal degradation, and IDOL overexpression using an adenoassociated viral (AAV) approach increases LDL-C in wild-type (WT) C57Bl/6 mice. 9, 11 Furthermore, transgenic overexpression of human IDOL in WT C57Bl/6 mice results in lipoprotein profiles similar to those of Ldlr À/À mice and results in concomitant atherosclerosis. 12 There is a strong association between suboptimal glycemic control and DKD; however, despite current antiglycemic therapies, diabetes can still be attributed to almost half of all end-stage renal disease cases. 2 Dyslipidemia, especially diabetic dyslipidemia with elevated triglyceride and low HDL cholesterol (HDL-C) levels, is an independent risk factor for progression of renal disease in individuals with T2D. 13 Our goal was twofold; to generate a much needed T2D mouse model of combined DKD and atherosclerosis and to investigate whether dyslipidemia worsens DKD. The LDL receptor was targeted for degradation by liver-specific AAV serotype DJ/8 (AAV-DJ/8)emediated overexpression of IDOL in BTBR WT and OB mice. We demonstrate generation of a T2D mouse model of combined DKD and atherosclerosis and show that IDOL-mediated dyslipidemia worsens diabetic albuminuria and glomerular macrophage accumulation.
Materials and Methods

Liver-Specific AAV-DJ/8
The AAV serotype DJ/8 exhibits high infectivity in vivo, 14 and is not known to cause disease or immune reactions. An AAV-DJ/8 encoding a degradation resistant mutant (K293R, K309R, K310R, K320R) IDOL, 10, 12 with bicistronic expression of enhanced green fluorescent protein (eGFP) under control of the liver-specific human thyroxinebinding globulin promoter was generated. The same AAV-DJ/8 that expressed liver-specific eGFP only was used as a control.
Mice
All animal work was approved by the Institutional Animal Care and Use Committee at the University of Washington.
Four-to 5-weekeold male BTBR WT or OB mice were injected retro-orbitally with 1 Â 10 11 viral genomes of AAV-DJ/8 containing eGFP or the human IDOL mutant. To increase uniformity of the study groups, only male mice were chosen for the study. Animals were randomized into each experimental group based on similar body weights with a target of 12 to 15 per group (statistically predetermined, based on power calculations). The viral dose was based on a pilot experiment. After the AAV injection, the animals were fed a semipurified, high-fat, cholesterolcontaining diet (40% of calories from fat, 1.25% added cholesterol; TD 00244, Enivgo, Madison, WI) 15 for 18 weeks. BTBR OB mice exhibit increased mortality after 24 weeks of age, preventing us from performing studies past this age. 5 To verify the effect of IDOL-induced dyslipidemia in the C57Bl/6 strain in which atherosclerosis is traditionally studied, WT and OB C57Bl/6 mice were injected with IDOL-AAV-DJ/8 and treated the same way as the BTBR mice. The high-fat diet used is not an obesogenic diet because WT C57Bl/6 mice had gained approximately 30% body weight after 17 weeks on diet. Body weights were monitored weekly, and glucose and plasma cholesterol were measured after 2, 8, and 18 weeks of diet. Lipid and glucose measurements were performed on ad libitum fed animals.
Albuminuria, Plasma Cystatin C, and Blood Urea Nitrogen
Urine was collected during a 4-to 6-hour fast in the last week of the study in specialized cages, in which the urine was collected into the bottom portion of the cage through a straining mesh. Urinary albumin was measured using a mouse albumin enzyme-linked immunosorbent assay and normalized to urinary creatinine levels (Albuwell, and Creatinine Companion, Exocell, Philadelphia, PA). Urinary volumes and total 24-hour urine and albumin secretion were also calculated ( Supplemental Table S1 ). Plasma cystatin C was measured using a cystatin C enzyme-linked immunosorbent assay (R&D Systems via Fisher Scientific, Hampton, NH), and plasma urea was measured using a Bioassay Systems Urea assay kit (Fisher Scientific). Blood urea nitrogen was calculated according to the manufacturer's instructions.
Lipid Measurements
Plasma triglycerides, nonesterified fatty acids, and cholesterol were measured using colorimetric assays from Sigma-Aldrich (St Louis, MO) and Wako Chemicals (Richmond, VA), respectively. Cholesterol lipoprotein profiles were determined as previously described 16 and very low-density lipoproteineC, LDL-C, and HDL-C were calculated from these. Cortex triglycerides were measured using the same colorimetric assay (Sigma-Aldrich) and normalized to milligrams of protein in the extracted tissue.
Analysis of Atherosclerosis and Kidney Histologic Analysis
At the end of the study, the mice were euthanized, blood was collected, and the animals were perfused gently with phosphate-buffered saline through the apex of the heart. The aorta, heart, brachiocephalic artery, liver, and kidneys were dissected out and placed in 10% neutral buffered formalin (Sigma-Aldrich). Another piece of liver was snap frozen for mRNA and protein analysis. The aortas (from the heart to the iliac bifurcation) were opened longitudinally, and atherosclerosis was determined en face after Sudan IV staining, as previously described. 15 The aortic sinus and a subset of aortas were sectioned, stained with Movat's pentachrome stain, and analyzed for lesion morphologic features. 15, 17 The kidneys were cut longitudinally, embedded in paraffin, and sectioned. A subset of kidneys were embedded in optimal cutting temperature embedding media, sectioned, and stained for neutral lipid deposition using Oil Red O. For ultrastructural analysis, kidneys were fixed in 10% neutral buffered formalin, postfixed in 1% osmium tetroxide, then processed and embedded in Eponate 12 resin using routine protocols. Approximately 0.1-mm sections were stained with uranyl acetate and lead citrate and examined using a Jeol JEM-1230 electron microscope. For analysis of RNA, the cortex was separated from the medulla and snap frozen. Periodic acideSchiff (PAS) and silver methenamine stains were used to quantify mesangial expansion. 5 Macrophage accumulation in the aorta and glomeruli was assessed using galectin-3 (Mac-2) immunostaining, which was performed after sodium citrate/ Tween antigen retrieval (monoclonal rat anti-mouse Mac-2 antibody: CL8942AP at 1 mg/mL; Cedarlane, Burlington, NC). For quantification of glomerular changes, 15 to 20 glomeruli were randomly photographed and the degree of glomerular matrix accumulation was quantified by computer image analysis [ImagePro Plus image analysis software version 7 (Media Cybernetics, Rockville, MD)], as previously described. 5 Podocyte numbers were estimated based on a method described by Venkatareddy et al. 18 Briefly, podocytes were identified using a p57 stain (SC8298 at 0.2 mg/mL; Santa Cruz Biotechnology, Dallas, TX), and glomerular podocytes were counted and their diameters measured to estimate the total number of podocytes per glomerulus. Mac-2epositive macrophages within glomeruli were counted in a minimum of 10 glomerular cross sections and expressed as the mean number of cells per glomerulus. For all stains, a negative control antibody of the same type and concentration was used. All histologic analyses were performed in a masked fashion.
Western Blot Analysis and Real-Time Quantitative PCR
For Western blot analysis, proteins were separated via SDS-PAGE and transferred to polyvinylidene difluoride Mylip (mouse and human)
membranes followed by incubation with the following antibodies: LDL receptor (goat polyclonal, AF2255 at 0.2 mg/mL; R&D Systems, Minneapolis, MN), glyceraldehyde-3-phosphate dehydrogenase (SC24778 at 0.2 mg/mL; Santa Cruz Biotechnology). Total RNA was isolated using Qiagen RNeasy Mini Kits. To remove trace genomic DNA, all samples were DNase treated. Real-time quantitative PCR was run using SYBR Green PCR Master Mix (Fermentas via Thermo Fisher Scientific, Waltham, MA), as described previously. 19 After each assay, a dissociation curve was run to confirm specificity of all PCR amplicons. All primer reactions were also analyzed on agarose gels for correct size and the presence of a single reaction product. Resulting Ct values were normalized to Rn18s, and the DDCt method was then used to express values as fold-over control samples. All samples were run in at least duplicates, and statistical analysis was performed on 2 À(DCt) values. Primer sequences used are given in Table 1 .
Statistical Analysis
All data are expressed as means AE SEM. Statistical analysis was performed using two-tailed unpaired t-test or one or two-way analysis of variance with Tukey's multiple comparison post hoc test for normally distributed data or Bonferroni multiple comparisons. Statistical outliers (Grubb's test) were excluded. P < 0.05 was considered statistically significant.
Results
IDOL Overexpression Results in Elevated Cholesterol Levels
To target degradation of the LDL receptor in the liver, AAV-DJ/8 that expressed a human degradationeresistant IDOL mutant under control of a liver-specific promoter 10, 11 was injected into 4-to 5-weekeold male WT and OB mice on the BTBR background. An AAV that expressed eGFP was used as control. After AAV injections, mice were fed a semipurified, high-fat, cholesterol-containing diet to promote atherosclerosis. 15 As expected, OB mice rapidly became obese, gaining more than 200% body weight during 18 weeks (weight gain was 210% AE 22% in eGFP OB mice and 211% AE 19% in IDOL OB mice). After 18 weeks, the BTBR OB mice weighed a mean of 25 g more than the BTBR WT controls ( Figure 1A ). Injection of IDOL-AAV did not alter obesity in WT or OB mice ( Figure 1A ). Furthermore, blood glucose levels were robustly elevated in both BTBR OB groups as early as 2 weeks (7 weeks of age) after initiation of diet ( Figure 1B ). Blood cholesterol levels were increased in leptin-deficient mice compared with WT mice, similar to previous reports, 5 albeit worsened by the high-fat, cholesterol-containing diet ( Figure 1C ). Plasma cholesterol levels were further increased in BTBR OB mice after IDOL expression, consistent with IDOL-mediated degradation of the LDL receptor ( Figure 1C) . Similarly, plasma triglyceride levels were elevated by leptin deficiency and further increased by IDOL expression ( Figure 1D ). Expression of human IDOL resulted in an approximately twofold increase in total expression of MYLIP (the gene encoding IDOL) using primers that detect both human and mouse MYLIP ( Figure 1E ). Human-specific primers only detected MYLIP in human IDOL-AAVeinjected mice (Supplemental Figure S1) . Consistent with increased expression of MYLIP, liver LDL receptor levels were reduced ( Figure 1F ) in BTBR WT and BTBR OB mice receiving IDOL-AAV. Lipoprotein profiles demonstrated that leptin deficiency resulted in increased LDL-C compared with BTBR WT mice, and this was further increased by 30% in mice expressing IDOL (Figure 1, G and H) . Together, IDOL-induced dyslipidemia is consistent with reduced liver LDL receptor levels and is primarily driven by increased LDL-C.
IDOL-Induced Dyslipidemia Augments Albuminuria and Glomerular Macrophage Accumulation
Dyslipidemia has been proposed to be a risk factor for progression of DKD in individuals with T2D. 13 To test whether IDOL-induced dyslipidemia would worsen DKD in BTBR OB mice, urine was collected during the last week of the study in fasting mice. Similar to a previous report, 5 BTBR OB mice have significantly elevated albumin/creatinine ratios compared with WT mice (Figure 2A ). This increase is driven by increased urinary albumin output because urinary creatinine levels were unchanged between the groups (Supplemental Figure S2A and Supplemental Table S1 ). IDOL-induced dyslipidemia in C57BL6 OB mice did not increase albuminuria above that of BTBR WT mice (Supplemental Figure S2B (data not shown). Interestingly, IDOL-induced dyslipidemia resulted in worsening of proteinuria, as assessed by albumin/ creatinine excretion, in BTBR OB mice (Figure 2A ) but did not alter plasma cystatin C and blood urea nitrogen (Supplemental Figure S2 , C and D).
Does IDOL-induced dyslipidemia worsen the histopathologic changes associated with DKD in BTBR OB mice? To address this question, kidneys were sectioned and stained for mesangial expansion using PAS and silver methenamine stains ( Figure 2B ). Glomerular hypertrophy was strikingly evident in both leptin-deficient groups, and IDOL-induced dyslipidemia did not alter glomerular hypertrophy (Figure 2 , B and C). Furthermore, BTBR OB mice exhibit a distinct expansion of the mesangium, and this phenotype also was not altered by IDOL-induced dyslipidemia ( Figures 2B and 3, A and B) . Again, the histopathologic kidney changes observed in BTBR OB mice are specific to the BTBR strain of mice because the glomeruli in C57Bl/6 OB mice were indistinguishable from those of BTBR WT mice (Supplemental Figure S2 absence of changes in genes involved in fatty acid oxidation (Cpt1a, Acox1, Ppara, and Ppargc1a) in the cortex (data not shown). Progression of DKD is also associated with injury and loss of podocytes in humans, 22, 23 and it has been previously found that BTBR OB mice have reduced podocyte numbers and density compared with WT mice. 24 Consistently, it was observed that leptin deficiency in BTBR mice results in significantly fewer podocytes compared with BTBR WT mice ( Figures 2B and 3E ). However, IDOL-induced dyslipidemia did not alter measures of podocyte loss in BTBR WT or OB mice. Further ultrastructural analysis of the glomeruli indicated that leptin-deficient BTBR mice had a notable mesangial expansion with areas of mesangiolysis and trapping of erythrocytes in the expanding matrix ( Figure 3F ), consistent with a previous report. 5 IDOL-induced dyslipidemia did not markedly alter those features. Furthermore, podocyte foot processes are focally effaced; however, this did not appear to be markedly increased in mice with IDOL-induced dyslipidemia ( Figure 3F ).
Glomerular macrophage accumulation has been proposed to be involved in kidney disease progression. 25e28 To investigate glomerular macrophage accumulation in the BTBR mice, kidneys were stained for the macrophage marker Mac-2. Consistent with previous data, 5, 24 leptin deficiency resulted in more Mac-2epositive cells per glomerulus, and IDOL-induced dyslipidemia further exacerbated the number of Mac-2epositive cells that accumulated per glomeruli under OB conditions ( Figure 3G ).
Macrophage accumulation correlated with urinary albumin/creatinine ratio (R 2 Z 0.37, P < 0.0001), potentially suggesting that the accelerated accumulation of macrophages may contribute to the increased albumin clearance. To further understand the increase in macrophage accumulation, mRNA from the renal cortex of all experimental groups was isolated and analyzed. Whereas leptin deficiency alone had no significant effect on inflammatory markers examined, the combination of leptin deficiency and IDOL-induced dyslipidemia markedly increased the expression of Ccl2, Vcam1, Icam1, and Il1b ( Figure 3H ). Together, these results suggest that IDOL-induced dyslipidemia worsens kidney function in diabetic BTBR OB mice through a process that may involve glomerular macrophage accumulation and local inflammation.
IDOL-Induced Dyslipidemia Results in Early Atherosclerotic Lesion Formation
At the end of the study, the extent of atherosclerosis was analyzed. Even though leptin deficiency in BTBR mice results in elevated cholesterol levels (approximately 400 mg/dL), BTBR OB mice injected with eGFP did not develop atherosclerosis during the 18-week study period, as detected by en face Sudan IV staining (Figure 4, A and B) . Furthermore, IDOL did not result in atherosclerotic lesion formation in BTBR WT mice but resulted in formation of atherosclerotic lesions only in BTBR OB mice (Figure 4 morphologic features, the aorta and the aortic sinus were sectioned and stained with Movat's pentachrome stain. Only BTBR OB animals with IDOL-induced dyslipidemia had detectable lesions in the aorta or the aortic sinus ( Figure 4 , C and D). The atherosclerotic lesions were generally small, especially in the aortic sinus, but lesions with a smooth muscleecontaining fibrous cap could be detected in the aorta of BTBR OB mice with IDOL-induced dyslipidemia ( Figure 4D ). These lesions also contained Mac-2epositive macrophages ( Figure 4C ). No lesions could be detected in any other group.
IDOL-Induced Dyslipidemia Results in Atherosclerosis in C57Bl/6 Mice
C57Bl/6 mice are prone to development of atherosclerosis if atherosclerotic dyslipidemia is induced, for example, by deleting the LDL receptor. 29 To investigate the effect of IDOL-AAV-DJ/8 on atherosclerosis in C57Bl/6 mice, WT and OB C57Bl/6 mice were injected with IDOL AAV and were then fed the high-fat, cholesterol-containing diet for 17 weeks. Similar to the BTBR mice, leptin deficiency resulted in marked weight gain (Supplemental Figure S3A ) and hypercholesterolemia (Supplemental Figure S3B) . In contrast to BTBR mice, leptin deficiency did not result in hyperglycemia in C57Bl/6 mice (Supplemental Figure S3C ). IDOL-induced dyslipidemia caused significant en face atherosclerosis in aortas of the C57Bl/6 OB mice, as well as clearly detectible lesions in the aortic sinus (Supplemental Figure S3 , DeF), reinforcing that IDOL-AAV-DJ/8 can be used as a tool to induce atherosclerosis and that C57Bl/6 is an atherosclerosis-susceptible genetic background.
Discussion
In the current study, we found the feasibility of using an AAV approach to target degradation of the LDL receptor in the BTBR mouse strain and thus render them susceptible to atherosclerosis. This approach circumvents the timeconsuming breeding that is commonly used to introduce proatherogenic dyslipidemia in mice and is adaptable to many different strains of mice. This is particularly important in the BTBR OB strain because this strain is susceptible to microvascular diabetes complications but does not develop significant atherosclerosis. Thus, the BTBR strain is known for its susceptibility to glucose dysregulation, 30 and with the deletion of the leptin gene, the BTBR OB mouse has emerged as one of the models that best mimics human DKD. 5, 24, 31 Furthermore, BTBR OB mice have signs of other microvascular complications, such as neuropathy and retinopathy, but are not hypertensive. 5, 32, 33 However, no atherosclerosis can be detected in BTBR OB mice without increasing LDL by reducing its clearance. The IDOL-AAV-DJ/8 approach rapidly generates a T2D mouse model of combined microvascular and macrovascular diabetes complications. Although the relative level of reduction of the LDL receptor could be improved on, this study clearly suggests that BTBR mice can be used to study atherosclerosis. Another strategy that successfully circumvented breeding onto proatherogenic backgrounds is overexpression of proprotein convertase subtilisin kexin 9 (PCSK9), which also results in reduced LDL receptor levels. 34 Both PCSK9 and IDOL result in elevated circulating levels of plasma cholesterol, with increases in primarily noneHDL-C. Overexpression of IDOL has previously been shown to elevate noneHDL-C levels. 9,12 IDOL overexpression using AAVs is another molecular tool in a scientist's toolbox to generate models of atherosclerosis.
Our study also reinforces that the commonly used C57Bl/ 6 strain for atherosclerosis is more susceptible to the development of atherosclerosis than the BTBR strain because these animals had larger and more advanced lesions than the BTBR mice.
Elevated glucose levels associated with diabetes have been proposed to be a major underlying mechanism of macrovascular and microvascular complications. 35 Clinical trials and epidemiologic studies clearly support the importance of suboptimal blood glucose control in development of microvascular diabetes complications 36 ; however, lipids have been suggested to play a pathologic role also in the progression of kidney disease. 37 Our results support this conclusion because IDOL expression resulted in worsened albuminuria in BTBR OB mice. A small meta-analysis and a secondary analysis from cardiovascular end point studies supports this finding. 38, 39 Furthermore, Kang et al 21 recently found that altered fatty acid metabolism is strongly correlated with progression to fibrotic renal disease. Falkevall et al 40 suggested that glomerular lipid deposition correlated with DKD. However, the larger Study of Heart and Renal Protection trial puts this into question because no beneficial effects on end-stage renal disease or estimated glomerular filtration rates were observed using statins to lower lipids. 41, 42 A recent retrospective study 13 that found that specific components of diabetic dyslipidemia (ie, low HDL-C and high triglyceride levels) were independent risk factors for progression of renal disease in individuals with T2D. Our data suggest that diabetic dyslipidemia indeed accelerates, at least some aspects, of DKD. Thus, IDOLinduced dyslipidemia results in increased urinary albumin secretion and was associated with increased macrophage accumulation and inflammation in glomeruli. This finding suggests that dyslipidemia might primarily accelerate the inflammatory component of DKD, which may be the mechanism that results in increased albuminuria in IDOL-induced dyslipidemia. Macrophages are known to accumulate in glomeruli and the interstitium in DKD and are present early in the disease pathogenesis. Macrophage chemokines, such as chemokine (C-C motif) ligand (CCL)-2, are known to be increased in diabetic kidneys and consistent with up-regulation of CCL-2. Macrophage numbers are also increased and correlate with disease stage in mouse models and humans with diabetes. 26, 28, 43 Consistently, preventing macrophage accumulation in glomeruli using CCL-2edeficient mice or, more recently, pharmacologic inhibition of CCR2 in humans improves urine albumin secretion under T2D conditions, implying a pathologic role of CCL-2emediated macrophage accumulation in DKD. 27,44e46 A testable hypothesis that emerges from the present study is that lipids stimulate macrophage accumulation in the glomerulus in DKD, similar to what happens in the artery wall, and that the underlying mechanisms are similar.
In summary, by inducing hepatic degradation of the LDL receptor, we generated a T2D model of combined DKD and atherosclerosis. This model provides a new tool to study mechanisms, interactions, and treatment strategies of kidney disease and atherosclerosis in T2D.
